BioSpace News Archive

Arbutus Biopharma Corporation today reports its first quarter 2022 financial results and provides pipeline updates.

XOMA Corporation reported its first quarter 2022 financial results and provided a recent operations update.

Context Therapeutics Inc. today announced that an abstract on the results of the monotherapy portion of its ongoing Phase 2 trial of lead candidate onapristone extended release (ONA-XR) in granulosa cell tumors of the ovary was accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, at the McCormick Place Convention Center in Chicago, IL.

Salarius Pharmaceuticals, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, May 12, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the three months ended March 31, 2022.

Intellia Therapeutics, Inc. today reported operational highlights and financial results for the first quarter ended March 31, 2022.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company.

HCW Biologics Inc. is presenting two groups of novel immunotherapeutics created with its proprietary and powerful Tissue factOr-Based fusIon (TOBI™) discovery platform at the 105th Annual Meeting of the American Association of Immunologists (AAI), or Immunology 2022.

Elevation Oncology, Inc. today announced financial results for the quarter ended March 31, 2022, and highlighted recent progress.

Marinus Pharmaceuticals, Inc. today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status epilepticus (RSE).

Synthetic Biologics, Inc. announced the strengthening of its oncology leadership team with the formation of a Scientific Advisory Board composed of key opinion leaders in oncolytic viruses and gene therapies.